$1,318.00
This Market Spotlight report covers the Neuroendocrine Tumors (NETs) market, comprising key marketed and pipeline drugs, clinical trials, probability of success, upcoming and regulatory events, a 10-year disease incidence and prevalence forecast, and licensing and asset acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Neuroendocrine Tumors (NETs) market, comprising key marketed and pipeline drugs, clinical trials, probability of success, upcoming and regulatory events, a 10-year disease incidence and prevalence forecast, and licensing and asset acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Subtypes
9 TREATMENT
9 Surgery
9 Hepatic artery embolization
9 Somatostatin analogs
9 Interferon-alpha (IFN-alpha)
9 Chemotherapy
10 Radiation therapy
10 Targeted therapy
10 Immunotherapy
10 Peptide receptor radionuclide therapy (PRRT)
10 Palliative care
12 EPIDEMIOLOGY
12 Incidence methodology
12 Epidemiological disease definition
16 Prevalence methodology
18 MARKETED DRUGS
22 PIPELINE DRUGS
30 KEY UPCOMING EVENTS
31 KEY REGULATORY EVENTS
31 Myrelez Launches In Norway
31 Surufatinib Among Latest New Filings In EU
31 Advanz Claims A First With German Lanreotide Launch
31 Hutchmed Bids To Bring Surufatinib To US
32 PROBABILITY OF SUCCESS
33 LICENSING AND ASSET ACQUISITION DEALS
33 Sanwa Kagaku Licenses Japanese Rights To Crinetics’ SST2 Agonist
33 NexImmune And Rutgers Enter Collaboration
33 Grand Acquires Greater China Rights To ITM Radiopharmaceutical Candidates
33 Amryt Predicts $1bn Revenues After Chiasma Acquisition
35 REVENUE OPPORTUNITY
37 CLINICAL TRIAL LANDSCAPE
38 Sponsors by status
39 Sponsors by phase
40 Recent events
41 BIBLIOGRAPHY
43 APPENDIX
LIST OF FIGURES
15 Figure 1: Trends in incident cases of NETs, 2019–28
16 Figure 2: Incident cases of NETs, by tumor type, 2019
22 Figure 3: Overview of pipeline drugs for NETs in the US
22 Figure 4: Pipeline drugs for NETs, by company
23 Figure 5: Pipeline drugs for NETs, by drug type
23 Figure 6: Pipeline drugs for NETs, by classification
30 Figure 7: Key upcoming events in NETs
32 Figure 8: Probability of success in the solid tumors pipeline
37 Figure 9: Clinical trials in NETs
37 Figure 10: Top 10 drugs for clinical trials in NETs
38 Figure 11: Top 10 companies for clinical trials in NETs
38 Figure 12: Trial locations in NETs
39 Figure 13: NETs trials status
40 Figure 14: NETs trials sponsors, by phase
LIST OF TABLES
14 Table 1: Incident cases of NETs, 2019–28
17 Table 2: Five-year prevalent cases of NETs, 2019–28
19 Table 3: Marketed drugs for NETs
24 Table 4: Pipeline drugs for NETs in the US
35 Table 5: Historical global sales, by drug ($m), 2017–21
36 Table 6: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!